A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies [4]

Leukemia

Volumn 20, Issue 7, 2006, Pages 1295-1297

  Slovak, M L ^a   Gundacker, H ^a   Bloomfield, C D ^b   Dewald, G ^c   Appelbaum, F R ^a   Larson, R A ^b   Tallman, M S ^c   Bennett, J M ^a   Stirewalt, D L ^a   Meshinchi, S ^d   Willman, C L ^a   Ravindranath, Y ^d   Alonzo, T A ^d   Carroll, A J ^b   Raimondi, S C ^d   Heerema, N A ^d  

^a Southwest Oncology Group   (United States)

^b Leukemia and Cytogenetics Committees for the Cancer and Leukemia Group B   (United States)

^c Leukemia and Cytogenetics Committees for the Eastern Cooperative Oncology Group   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; CANCER STAGING; CANCER SURVIVAL; CHILD; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 6; CHROMOSOME TRANSLOCATION 9; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE INSERTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; KARYOTYPING; LETTER; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 33745184051     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404233     Document Type: Letter

References (9)

1. Huret JL. t(6;9)(p23;q34). Atlas Genet Cytogenet Oncol Haematol January 1998. 2005, URL: http://www.infobiogen.fr/services/chromcancer/ index.html.
2. Alsabeh R, Brynes RK, Slovak ML, Arber DA. Acute myeloid leukemia with t(6;9)(p23;q34): Association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol 1997; 107: 430-437.
3. Oyarzo M, Lin P, Glassman A, Bueso-Ramos CE, Luthra R, Medeiros LJ. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of FLT3 gene mutations. Am J Clin Pathol 2004; 122: 348-358.
4. Garçon L, Libura M, Delabesse E, Velensi F, Asnafi F, Berger C et al. DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Leukemia 2005; 19: 1338-1344.
5. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood First Edition Paper, prepublished online February 2, 2006; doi: 10.1182/ blood-2005-09-3724 (in press).
6. Stirewalt DL, Meshinchi S, Kussick SJ, Sheets KM, Pogosova-Agadjanyan E, Willman CL et al. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br J Haematol 2004; 124: 481-484.
7. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
8. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil K, Mohamed AN et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia (AML): A Southwest Oncology/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075-4083.
9. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of hematological malignancies report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000; 13: 193-207.